Nuformix plc

0.11pAs of Sun 8 Nov 2026, 12:00 UTC

LSE:NFXHealthcare

Ctry United Kingdom

PE (Fwd) •••

TSR 9Y CAGR (30.57%)

Div yield —

ROE (50.94%)

Biotechnology

Beta (5Y) 1.71

PE TTM —

TSR TTM (72.37%)

Mkt cap £2.871M

ROIC (89.28%)

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

0.132p

19.60%

307.71%

Sell 2|9|10|5|10

TTM

FYE 30 Sep GBP

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

FY2027E

Trend

5Y

10Y

Peers

0.112

Revenue£M

0.446

0.450

0.448

0.442

0.448

0.442

0.451

0.463

0.457

0.116

0.136

0.71%

0.44%

24

11.52

Revenue growth%

1.63

0.40

0.44

0.40

0.40

0.68

0.40

0.40

0.40

13.59

7.21

0.40

0.40

17

3.90

Gross margin%

21.71

23.72

23.42

22.40

25.36

28.29

26.59

27.08

30.06

20.97

12.31

27.08

24.54

36

2.60

Operating margin%

0.40

0.40

0.40

2.38

0.40

1.07

3.02

3.57

0.76

17.04

3.29

1.07

0.58

39

21.66

Net margin%

23.10

21.68

23.87

23.43

24.97

26.03

23.48

21.87

23.27

8.54

25.98

23.48

23.45

57

12.11

P/E ratio (avg)x

32.39

35.47

32.52

30.89

27.37

27.44

24.57

25.81

22.66

24.05

18.30

25.81

29.16

36

36.03

EV/EBITx

22.20

24.98

24.26

24.95

24.07

27.88

29.50

34.10

33.39

25.63

23.72

29.50

24.96

87

20.30

FCF yield (avg)%

17.84

16.23

17.53

19.12

22.06

19.44

19.17

18.69

20.32

2.46

5.08

19.44

19.15

45

18.54

FCF margin%

26.77

27.78

29.83

29.56

30.30

27.98

28.65

31.64

34.20

28.20

25.72

30.30

29.11

84

0.374

FCF / Net incomex

0.810

0.717

0.724

0.664

0.690

0.631

0.651

0.695

0.624

1.040

1.627

0.651

0.692

43

15.28

ROIC%

8.37

9.72

8.35

8.82

5.91

4.75

6.86

8.76

9.84

14.32

25.60

6.86

8.36

94

21.89

Return on equity%

4.72

7.49

6.37

5.40

3.40

4.66

6.62

7.12

10.05

28.86

12.53

6.62

6.50

23

12.10

Return on assets%

2.42

0.40

2.78

2.29

3.73

3.50

5.90

7.06

9.24

5.36

24.64

5.90

3.14

62

—

EPS£

—

—

—

—

—

—

—

—

—

—

—

3.21%

2.03%

—

5.49

EPS growth%

27.65

27.15

28.28

25.53

28.30

30.29

27.47

26.64

26.08

29.77

10.27

27.47

27.31

57

—

Bookvalue per sh£

—

—

—

—

—

—

—

—

—

—

—

(0.85%)

(3.37%)

—

—

FCF per share£

—

—

—

—

—

—

—

—

—

—

—

4.52%

2.83%

—

—

Dividend per sh£

—

—

—

—

—

—

—

—

—

—

—

16.14%

10.04%

—

8.10

Div yield (avg)%

16.09

14.14

15.31

13.75

14.20

11.85

12.50

13.72

16.20

16.14

4.50

13.72

14.17

74

8.94

Payout ratio%

0.40

2.09

4.84

4.21

3.04

0.84

0.40

1.44

4.35

26.61

12.06

1.44

1.76

18

2.651

Shares (diluted)B

2.767

2.610

2.716

2.846

2.817

2.522

2.454

2.174

2.068

2.539

2.639

(6.19%)

(3.21%)

6

8.96

Buyback yield%

9.02

11.55

8.84

8.44

6.84

8.10

9.62

11.22

13.57

19.73

12.17

9.62

8.93

11

0.360

D/E ratiox

0.972

0.871

0.747

0.640

0.576

0.600

0.522

0.472

0.482

0.830

0.985

0.522

0.620

41

0.253

Enterprise value£M

0.283

0.293

0.301

0.330

0.291

0.301

0.274

0.285

0.295

0.272

0.191

(2.18%)

(1.41%)

28

0.387

LT debt£M

0.410

0.422

0.464

0.445

0.510

0.518

0.575

0.586

0.612

0.262

0.406

6.57%

4.28%

16

Peers (US$3.863M)

Cap (US$)

PE

Futura Medical plc

4.169M

—

4.041M

—

2.665M

—

PharmaCyte Biotech…

3.865M

—

Capital

TTM

5Y

10Y

Leveragex

0.889

0.439

0.463

EBIT/Intx

0.195

0.108

0.133

Own earn%

151.71

(25.72)

(12.05)

Sh yield%

17.06

22.12

23.18

Owners

Insiders/Inst%

12.33

36.65

Short interest%

0.66

SBC / revenue%

0.26

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

20

Op margin range%

0–4

$1 testx

—

Incr. ROIC%

−1

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

£0.457M

0.44%

1.00×

Cost of revenue

£0.241M

0.93%

1.05×

Operating expenses

£0.072M

(0.22%)

0.94×